Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory

Statement From the HF Collaboratory

Ankeet S. Bhatt, MD, MBA; William T. Abraham, MD; JoAnn Lindenfeld, MD; Michael Bristow, MD; Peter E. Carson, MD; G. Michael Felker, MD, MHS; Gregg C. Fonarow, MD; Stephen J. Greene, MD; Mitchell A. Psotka, MD, PHD; Scott D. Solomon, MD; Norman Stockbridge, MD, PHD; John R. Teerlink, MD; Muthiah Vaduganathan, MD, MPH; Janet Wittes, PHD; Mona Fiuzat, PHARMD; Christopher M. O'Connor, MD; Javed Butler, MD, MPH, MBA


JACC Heart Fail. 2021;9(1):1-12. 

In This Article

Pharmacogenomic Approaches

"Omics" technology may allow for better disease genotyping and phenotyping based on pathophysiology that extends beyond traditional classifications.[40,41] A deeper understanding of fundamental biology could allow for more accurate prediction as to which patients may benefit from a particular therapy, creating a personalized approach. Particular proteomic signatures have been used to define patients at risk for incident HF[42] and to distinguish severity of HF phenotypes.[43] Application of these signatures and others may allow for the further study of differential pharmacogenomic effects of standard-of-care therapies as well as new therapies currently under investigation.